BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Bioanalytical Technologies Introduces Enhanced Drug Discovery Services


2/16/2011 8:08:43 AM

WEST LAFAYETTE, IN--(Marketwire - February 15, 2011) - BASi (Bioanalytical Systems Inc.) (NASDAQ: BASI), a leader in drug development and research instrumentation, is introducing the ability to work with large animals to its Culex ® Automated In Vivo Discovery Services. The process offers extensive, faster, and more meaningful results to help develop new drugs while easing the stress on animals. The life sciences company, based in the Purdue Research Park, is also announcing the addition of non-clinical scientist Brad Gien to its Culex services team.

BASi focuses on developing innovative services and products that increase efficiency and reduce costs associated with taking new drugs to market. The Culex Automated In Vivo Sampling Services have long offered investigators a means to increase the amount and type of data gathered in drug discovery experiments with small animal models. Large animal models are now being offered. By offering small to large animal studies, clients will have a broad range of options in study design. By merging BASi expertise in instrumentation with an outstanding history of service, BASi will provide clients access to better data to make earlier, more informed decisions about compounds.

The Culex allows programmed sampling of blood and other body fluids without human intervention any time of the day or night or continuously for 24-hours or more. This integrative approach reduces animal usage while providing stronger data. "One major benefit of automated sampling is reduced stress in the subject," says Craig Bruntlett, senior vice president of instrumentation. "Stress can create a significant impact on the physiological parameters and can make data difficult to interpret. Reducing stress for the animal can lead to cleaner, more meaningful data."

Brad Gien joins BASi with ten years of experience in biomedical research, extensive rodent surgery capability, and familiarity with the automated Culex system. "His experience and surgical skills will expand the capability of the BASi PK/PD laboratory in Mt. Vernon, Indiana," says Director of Toxicology David Hopper.

About BASi
BASi is a drug discovery and services development company providing contract research services and research instruments and supplies to the world's leading pharmaceutical companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking new and generic drugs to market. Visit www.BASInc.com for more about BASi.

This release contains forward-looking statements that are subject to risks and
uncertainties including, but not limited to, risks and uncertainties related to changes
in the market and demand for our products and services, the development,
marketing and sales of products and services, changes in technology, industry
standards and regulatory standards, and various market and operating risks detailed
in the company's filings with the Securities and Exchange Commission.



Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->